|
This is a very promising result. It compares cyclophosphamide alone, rather than in combination with methotrexate or sirolimus, for preventing graft-versus-host disease after a stem cell transplant with matched related or unrelated donors.
When cyclophosphamide is used alone, it is reportedly good at reducing unwanted T cells without harming "good" T cells, and that's a key to avoiding GVHD. Overall, 87% of their study subjects avoided chronic GVHD.
|